Small bowel angioedema is acute or recurrent small bowel wall thickening caused by intestinal wall edema. The most common cause is drug-induced angioedema — particularly angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). Hereditary angioedema (C1 esterase inhibitor deficiency) is a rare but important cause. Allergic reactions and idiopathic angioedema constitute other etiologies. Clinically presents with abdominal pain, nausea, vomiting, and diarrhea; severe cases may develop intestinal obstruction. On imaging, diffuse, symmetric wall thickening and submucosal edema (target sign) are characteristic. The condition is generally reversible — rapidly resolves with discontinuation of the triggering agent or C1 inhibitor replacement.
Age Range
20-65
Peak Age
40
Gender
Equal
Prevalence
Rare
The fundamental pathophysiological mechanism in angioedema is submucosal and subserosal edema due to increased vascular permeability. In ACE inhibitors, bradykinin degradation is inhibited → bradykinin accumulation → increased vascular permeability → plasma leakage → wall edema. In hereditary angioedema, C1 esterase inhibitor deficiency → complement and contact system activation → excessive bradykinin production → same vascular leakage mechanism. Submucosal edema in the intestinal wall creates the 'target sign' on imaging — a hypodense/hypointense submucosal edema layer between enhancing mucosa and serosa. Edema shows symmetric and diffuse distribution because the mechanism is systemic; this is important for differentiation from focal neoplastic or inflammatory thickening. Mesenteric vascular structures are unaffected — distinguishing from ischemic bowel disease.
Three-layered 'target' appearance on CT created by a hypodense submucosal edema layer between enhancing mucosa and serosa. In angioedema, this finding is diffuse and symmetric — observed in multiple small bowel loops. Combined with drug history (ACE inhibitor), it is diagnostically directing.
Target sign in the small bowel wall on portal venous phase — hypodense submucosal edema layer between enhancing inner mucosa and outer serosa/muscularis layer. Wall thickness is generally 5-15 mm with smooth, symmetric thickening. The submucosal layer shows values close to water density (10-25 HU). This pattern is diffuse with jejunal predominant distribution.
Report Sentence
Diffuse, symmetric wall thickening with submucosal edema ('target sign') in the small bowel is observed, consistent with angioedema.
Wall thickening shows jejunal predominant distribution — duodenum and jejunum are the most commonly involved segments. Ileum is generally less affected. Thickening is homogeneous and symmetric along a long segment. Bowel folds (valvulae conniventes) appear thickened but regular. Colon is generally uninvolved or minimally involved.
Report Sentence
Diffuse small bowel wall thickening with jejunal predominance is observed, consistent with ACE inhibitor-related angioedema or hereditary angioedema.
Free fluid (ascites) around small bowel loops and edema findings in mesenteric fat tissue on portal venous phase. Ascites is generally small to moderate in amount, accumulating in the pelvis and Morrison's pouch. Increased density (haziness) in mesenteric fat tissue and fluid around mesenteric vascular structures may be seen. Pleural effusion may also be present — part of systemic capillary leak.
Report Sentence
Ascites and mesenteric edema accompanying small bowel wall thickening are observed, consistent with systemic capillary leak syndrome / angioedema.
Prominent mucosal enhancement in the arterial phase — indicator of mucosal hyperemia and increased vascular permeability. The mucosa enhances more intensely than the serosa/muscularis layer, creating a prominent contrast difference with the submucosal edema layer. This 'mural stratification' pattern reflects active vascular leakage.
Report Sentence
Prominent enhancement increase due to mucosal hyperemia and mural stratification are observed in the arterial phase.
Markedly hyperintense signal in the submucosal layer on T2-weighted images — reflecting water accumulation. While the mucosa and serosa/muscularis layer show intermediate signal, the submucosal edema layer produces very bright T2 signal due to free water content. This mural stratification is more prominently visualized on MRI than CT. When luminal distension is achieved with MR enterography, wall stratification is optimally evaluated.
Report Sentence
Prominent submucosal T2 hyperintensity and mural stratification in the small bowel wall on T2-weighted images are observed, consistent with angioedema.
Diffuse small bowel wall thickening (>3 mm) on B-mode ultrasound with characteristic layered appearance — hyperechoic submucosal edema layer surrounded by hypoechoic muscle layer. Peritoneal free fluid (ascites) is seen as anechoic areas between bowel loops. US is useful for rapid diagnosis and follow-up but does not provide as detailed evaluation as CT/MRI.
Report Sentence
Diffuse wall thickening with layered appearance and peritoneal free fluid in the small bowel on ultrasound are observed, consistent with angioedema.
Criteria
Intestinal angioedema developing under ACE inhibitor use — most common cause
Distinct Features
Completely resolves within 24-72 hours after drug discontinuation. Facial/lip angioedema may accompany but intestinal involvement may be isolated. Can develop years after initiation of use.
Criteria
C1 esterase inhibitor deficiency or dysfunction — autosomal dominant inheritance
Distinct Features
Recurrent attacks (history of episodic abdominal pain). Positive family history. Low C4 level (screening test). Treatment with C1 inhibitor replacement or bradykinin receptor antagonists. Extremity and facial edema may accompany.
Criteria
Angioedema due to IgE-mediated mast cell degranulation — food/drug/insect sting trigger
Distinct Features
Rapid onset (minutes-hours), urticaria and anaphylaxis may accompany. Rapid response to antihistamines and epinephrine. Intestinal involvement is rarer but may be seen in severe allergic reactions.
Distinguishing Feature
In ischemia, mesenteric vascular pathology (thrombosis/embolism) is present with segmental involvement and asymmetric thickening; in angioedema, mesenteric vessels are normal and involvement is diffuse/symmetric
Distinguishing Feature
In Crohn's, skip lesions, mesenteric 'comb sign', fistula/sinus tracts, and asymmetric involvement; in angioedema, diffuse symmetric involvement and rapid resolution
Distinguishing Feature
In celiac disease, jejunal fold reversal and ileal thickening; in angioedema, submucosal edema ('target sign') is predominant
Distinguishing Feature
In radiation enteritis, involvement limited to radiation field with pelvic radiotherapy history; in angioedema, diffuse involvement and drug/allergy history
Urgency
urgentManagement
medicalBiopsy
Not NeededFollow-up
specialist-referralIn ACE inhibitor-related angioedema, immediate treatment is drug discontinuation — dramatic improvement is generally seen within 24-72 hours. In hereditary angioedema, C1 inhibitor concentrate (Berinert, Cinryze), bradykinin B2 receptor antagonist (icatibant), or kallikrein inhibitor (ecallantide) is used. In allergic angioedema, antihistamines and epinephrine in severe cases are given. If obstruction findings are present, decompression (nasogastric tube) may be needed. Drug history is critically important — should be asked and ACE inhibitor discontinued with alternative antihypertensive started.
Intestinal angioedema is usually self-limited and resolves with removal of the trigger. ACE inhibitor should be discontinued, and C1 esterase inhibitor replacement is needed for hereditary forms. Long-term prophylaxis is required for recurrent attacks.